AstraZeneca PLC (ETR:ZEG)

Market Cap	219.58B
Revenue (ttm)	52.23B
Net Income (ttm)	6.80B
Shares Out	n/a
EPS (ttm)	4.35
PE Ratio	32.31
Forward PE	n/a
Dividend	2.93 (2.09%)
Ex-Dividend Date	Feb 20, 2025

Volume	10,320
Average Volume	17,701
Open	140.65
Previous Close	140.40
Day's Range	140.00 - 142.35
52-Week Range	117.30 - 158.20
Beta	0.20
RSI	61.22
Earnings Date	Feb 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 89,900
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: ZEG

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD